February 4, 2012
Pharmacy news, jobs, continuing education, community and more.
The discovery of a new class of dual-acting antimalarial compounds – the imidazolopiperazines (IZPs) – was published in the journal Science online, at the Science Express website today[1]. The findings report on compounds that target both liver and blood infections, attacking the Plasmodium parasite at both stages in its reproduction cycle. The findings describe how [...]
Novartis announced the appointment of Timothy Wright, M.D. as Global Head, Development, Novartis Pharmaceuticals effective immediately. Dr Wright joined Novartis in 2004 and most recently served as Senior Vice President and Global Head of Translational Sciences at Novartis Institutes for BioMedical Research (NIBR). His group included Translational Medicine, Biomarker Development, Preclinical Safety (toxicology), and Drug [...]
Basel, – Novartis announced today that the Company has started shipping seasonal influenza vaccine to its US customers for the 2011-2012 influenza season. Early delivery of seasonal influenza vaccine will ensure healthcare professionals have the ability to provide the earliest possible protection against influenza. Novartis plans to ship over 30 million doses of Fluvirin® influenza [...]
Basel, – Novartis announced today that an interim analysis of a pivotal Phase III study showed Afinitor® (everolimus) tablets in combination with exemestane significantly extended progression-free survival (PFS), or time without tumor growth, when compared to placebo plus exemestane in women with advanced breast cancer. The trial was stopped early after interim results showed the [...]
Basel, – Novartis announced today that the US Food and Drug Administration (FDA) has approved once-daily Arcapta(TM) Neohaler(TM) (indacaterol inhalation powder) 75 mcg for the long-term maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema[1]. Arcapta is not indicated for acute deteriorations of COPD or [...]
Basel, July 1, 2011 – Novartis announced today that it has received regulatory approval in Japan for Onbrez® Inhalation Capsules (indacaterol) 150 mcg once-daily for the treatment of chronic obstructive pulmonary disease (COPD). Onbrez is the only once-daily COPD therapy to combine improvements in lung function lasting for 24 hours[1],[2],[3] with a rapid onset of [...]
Basel, March 21, 2011 – The European Commission has granted Novartis approval for Gilenya® (fingolimod) 0.5 mg daily as a disease modifying therapy in patients with highly active relapsing-remitting multiple sclerosis (RRMS) despite treatment with beta interferon, or in patients with rapidly evolving severe RRMS. “Today marks an important step forward in the way we [...]
Basel, March 17, 2011 – Novartis has committed to providing the equivalent of over USD 3 million in immediate relief aid to the victims of the recent earthquake in Japan. The support includes both direct financial aid to relief agencies as well as donations of essential medicines, including pain relieving drugs. “It is still difficult [...]
Basel, February 9, 2011 – The New England Journal of Medicine (NEJM) published a study today that shows Afinitor® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival (PFS), or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (NET)[1]. Data from the study, RADIANT-3 (RAD001 [...]
Basel, March 18, 2010 – Novartis announced today that the European Commission (EC) granted a Marketing Authorization for Menveo® (Meningococcal Group A, C, W135 and Y conjugate vaccine) in all 27 European member states. Menveo is indicated for the active immunization of adolescents (from 11 years of age) and adults at risk of exposure to [...]
Bristol-Myers Squibb Company (NYSE:BMY) and Inhibitex, Inc. (Nasdaq:INHX) announced today that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire Inhibitex for
Novartis Consumer Health Inc. (NCH) informed customers, that it is voluntarily recalling all lots of select bottle packaging configurations from retailers of Excedrin® and NoDoz® products with expiry
This past June in a tiny pharmacy in the sleepy suburban town of Medford, New York, a deranged gunman high on prescription drugs executed four innocent victims in cold blood. “In all of my law … [Read More...]
© Rx Times, LLC 2011. All rights reserved. All products denoted with ™ and ® are trademarks or registered trademarks of Rx Times, LLC and/or its affiliates.